HER2 유방암 검사 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The HER2 Breast Cancer Test Market size is expected to reach USD 781.85 Million in 2034 from USD 433.96 Million (2025) growing at a CAGR of 6.76% during 2026-2034.

The Global HER2 Breast Cancer Test Market is expanding significantly due to the growing incidence of breast cancer worldwide and the rising importance of early diagnosis. HER2 testing plays a critical role in determining targeted treatment strategies, particularly for patients who may benefit from HER2-directed therapies. Increasing adoption of advanced diagnostic technologies such as immunohistochemistry and in situ hybridization is strengthening market demand. Healthcare providers are increasingly emphasizing precision diagnostics to improve survival rates and treatment effectiveness.

Market growth is driven by the expansion of screening programs, improved laboratory infrastructure, and rising awareness among patients about genetic and biomarker testing. Pharmaceutical advancements in HER2-targeted therapies are further increasing the need for accurate and reliable testing solutions. Government support for cancer research and reimbursement policies for diagnostic testing are also encouraging broader adoption. Additionally, technological innovations are enhancing test accuracy, turnaround time, and automation in clinical laboratories.

In the future, the HER2 Breast Cancer Test Market is expected to benefit from advancements in molecular diagnostics and digital pathology. The integration of artificial intelligence in diagnostic workflows may further improve accuracy and efficiency. Emerging markets are likely to witness increased testing adoption due to improving healthcare access. As personalized medicine continues to shape oncology treatment, HER2 testing will remain a critical component of breast cancer management strategies worldwide.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Test Type

• Immunohistochemistry (IHC)
• Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH)

By End-user

• Hospitals
• Diagnostic Laboratories
• Others

COMPANIES PROFILED

• Abbott Molecular Inc, Biogenex Laboratories Inc, Leica Biosystems, Roche, Agilent Technologies, Mylab Discovery Solutions Pvt Ltd, Jiangsu HengRui Medicine Co, Ltd, Shanghai Henlius Biotech, Merus NV, GeneQuantum
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL HER2 BREAST CANCER TEST MARKET: BY TEST TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Test Type
• 4.2. Immunohistochemistry (IHC) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HER2 BREAST CANCER TEST MARKET: BY END-USER 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End-user
• 5.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HER2 BREAST CANCER TEST MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Test Type
  • 6.2.2 By End-user
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Test Type
  • 6.3.2 By End-user
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Test Type
  • 6.4.2 By End-user
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Test Type
  • 6.5.2 By End-user
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Test Type
  • 6.6.2 By End-user
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL HER2 BREAST CANCER TEST INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Abbott Molecular Inc
  • 8.2.2 Biogenex Laboratories Inc
  • 8.2.3 Leica Biosystems
  • 8.2.4 Roche
  • 8.2.5 Agilent Technologies
  • 8.2.6 Mylab Discovery Solutions Pvt. Ltd
  • 8.2.7 Jiangsu HengRui Medicine Co.Ltd
  • 8.2.8 Shanghai Henlius Biotech
  • 8.2.9 Merus N.V
  • 8.2.10 GeneQuantum